Quick Answer
Aligos Therapeutics, Inc. reported Total Revenue of $2.19 million for the year ending 2025.
- Aligos Therapeutics, Inc. showed a decrease of -39.5% in Total Revenue from 2024 to 2025.
- This data is from Aligos Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 5, 2026.
- XBRL data for this metric is available from 2023 to 2025 (3 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2022: $0.00 | Q3 2022: $0.00 | Q1 2023: $140.0 thousand | Q2 2023: $4.29 million | Q3 2023: $1.09 million | Q1 2024: $694.0 thousand | Q2 2024: $1.06 million | Q3 2024: $1.25 million | Q1 2025: $311.0 thousand | Q2 2025: $965.0 thousand | Q3 2025: $741.0 thousand.
- Over the full 3 years of available data (2023 to 2025), Aligos Therapeutics, Inc.'s Total Revenue has declined by 64.7%.
- Historical annual values: Fiscal year 2025: $2.19 million | Fiscal year 2024: $3.61 million | Fiscal year 2023: $6.19 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: